Oncocross Co., Ltd. (KOSDAQ:382150)

Market Cap	156.32B
Revenue (ttm)	1.07B
Net Income (ttm)	-7.26B
Shares Out	11.90M
EPS (ttm)	-670.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	658,083
Average Volume	2,164,898
Open	13,270
Previous Close	13,270
Day's Range	12,940 - 13,630
52-Week Range	6,260 - 16,700
Beta	n/a
RSI	51.86
Earnings Date	Aug 12, 2025

About Oncocross

Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis. The company is also developing OJP3101 for metabolic disease; OJP3101 for Cardiovascular D...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 382150

Financial Performance

In 2024, Oncocross's revenue was 1.07 billion, an increase of 1071.49% compared to the previous year's 91.52 million. Losses were -6.48 billion, 53.8% more than in 2023.